High Tech Medical Kft.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At High Tech Medical Kft. investigators are studying atherosclerotic cardiovascular disease and related high‑risk conditions, evaluating new lipid‑lowering therapies and strategies to reduce major adverse cardiovascular events.
- Evaluation of novel lipoprotein(a) lowering agents
- Impact of PCSK9 inhibition on heart disease risk
- Management of heterozygous familial hypercholesterolemia
- Cardiovascular outcomes in patients with elevated LDL‑C
The trials aim to improve prevention and treatment of heart attacks, strokes, and vascular complications, advancing personalized cardiology.
Nervous System Diseases
Research focuses on migraine, both chronic and episodic, testing monoclonal antibodies that target CGRP pathways to lower monthly migraine days.
- Erenumab efficacy in pediatric migraine
- Comparative studies of migraine preventive therapies
- Long‑term safety of CGRP‑targeted treatments
- Quality‑of‑life outcomes for migraine patients
The goal is to provide better preventive options and improve daily functioning for individuals suffering from debilitating headaches.
Nutritional and Metabolic Diseases
The site conducts trials on non‑alcoholic steatohepatitis (NASH) and metabolic dysfunction‑associated steatohepatitis (MASH) with compensated cirrhosis, assessing agents that may reverse liver fibrosis and improve metabolic health.
- Lanifibranor effects on liver histology
- Pegozafermin impact on fibrosis regression
- Therapeutic strategies for hyperlipidemia and familial hypercholesterolemia
- Biomarker development for liver disease progression
These studies seek treatments that halt or reverse liver damage and address lipid disorders, supporting patients with metabolic syndrome.
Respiratory Tract Diseases
Investigations target refractory and unexplained chronic cough, evaluating novel oral compounds designed to reduce cough frequency and improve patient comfort.
- BLU‑5937 efficacy on 24‑hour cough count
- Safety profile of chronic cough therapeutics
- Patient‑reported outcomes for cough severity
- Mechanistic insights into cough reflex modulation
The purpose is to develop effective therapies for chronic cough, a condition with limited treatment options.
Skin and Connective Tissue Diseases
Clinical work includes chronic spontaneous urticaria, comparing new biologics with established therapy to achieve symptom control in patients unresponsive to antihistamines.
- BP11 versus Xolair in chronic urticaria
- Assessment of disease activity scores
- Long‑term safety of biologic treatments
- Impact on patient quality of life
These studies aim to expand therapeutic choices for persistent hives and improve daily wellbeing.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Amgen Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in High Tech Medical Kft.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) | Amgen Inc. | Phase III | Not Recruiting | Jul 2019 | Jan 2026 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Erenumab | 2 | Unknown | 2019-07-19 | 2019-07-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.